Filing summary: Sharps Technology, Inc. — Form 10-Q
Period: Quarter and six months ended June 30, 2022. The request metadata names Skyai, Inc., but the supplied filing is for Sharps Technology, Inc. (Nasdaq: STSS, STSSW); verify the issuer before relying on this summary.
Business context and financial highlights
Sharps is a pre-revenue medical-device company developing patented safety syringes and pursuing commercialization. It reported no revenue in the quarter or first half of 2022 or the comparable 2021 periods. Gross margin and operating margin are therefore not meaningful.
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| R&D expense | $556,868 | $1,063,243 |
| G&A expense | $2,230,801 | $3,061,710 |
| Operating loss | $(2,787,669) | $(4,124,953) |
| Net income (loss) | $477,754 | $(1,391,967) |
| Basic and diluted earnings (loss) per share | $0.06 | $(0.20) |
The quarter’s reported profit reflected a $4.37 million fair-value gain on contingent stock and warrant liabilities, partly offset by $1.10 million of interest expense. These valuation changes are not operating revenue. For the six months, the company recorded a $4.08 million fair-value gain but still reported a net loss.
Liquidity, cash flow, and debt
- At June 30, cash was $7.81 million, versus $1.48 million at December 31, 2021. Working capital was $4.95 million, compared with a $1.16 million deficit at year-end.
- First-half operating cash use was $3.09 million; investing cash use was $2.81 million, including $2.35 million in acquisition escrow and $463,355 for machinery and equipment.
- Financing activities provided $12.24 million, primarily from approximately $14.2 million of IPO proceeds, less repayment of the $2.0 million note. The note, which carried an 8% stated rate and substantial accretion of debt discount, was repaid in April.
- Current liabilities included a $2.47 million warrant liability. The IPO warrants are liability-classified and remeasured at fair value, which can materially affect reported results.
Changes versus prior comparable periods
- Quarterly R&D expense rose 48% year over year, to $557,000; quarterly G&A rose 412%, to $2.23 million. The company cited increased facility and product-development costs, staffing and consulting, stock compensation, professional and public-company costs, and warrant issuance costs.
- For the six months, R&D increased 26% and G&A increased 247% year over year. Operating cash use also increased from $1.41 million to $3.09 million.
- Six-month net loss narrowed from $1.73 million to $1.39 million, primarily reflecting noncash fair-value gains; operating expenses and cash burn increased.
- The IPO and related share and warrant issuances increased common shares outstanding to 9,207,415 at June 30, from 5,187,062 at December 31, 2021.
Outlook, developments, and risks
- Management expects R&D spending to increase as it continues developing the Sharps Provensa product line. It provided no revenue or earnings guidance.
- The company said commercial quantities of inventory are needed to secure orders. It had $127,441 of inventory at June 30, consisting of raw materials.
- The acquisition of Safegard Medical’s manufacturing facility in Hungary closed on July 8, 2022, after quarter-end. The company reported $2.5 million in escrow at June 30; $2.45 million was released at closing and $50,000 remained held for transfer taxes. Before closing, it paid facility operating costs, recorded as R&D expense.
- Management reported no material change to the risk factors in the IPO prospectus and no material litigation or other loss contingencies. Key business risks include the lack of revenue, continuing cash use, commercialization and manufacturing execution, and reliance on estimates and warrant valuations.
- Management concluded disclosure controls were effective as of quarter-end and reported no material change in internal control over financial reporting. The company identified itself as an emerging growth company and smaller reporting company.
Important facts for investors to verify
- Confirm the issuer: the supplied document is Sharps Technology, Inc., not Skyai, Inc.
- Review the Safegard acquisition’s post-close costs, integration, manufacturing readiness, and remaining escrow obligations.
- Assess cash runway against operating and investing cash use, and whether commercial orders and revenue materialize.
- Evaluate potential dilution from warrants and options; the filing reports 10,452,773 potentially dilutive options and warrants excluded from diluted EPS as antidilutive.
- Check warrant-liability fair-value calculations and reported amounts: the notes show $2,465,820 total, while the component disclosure includes a figure that differs by $1,000 in one location.